Risperidone in the treatment of psychosis of alzheimer disease: Results from a prospective clinical trial
Abstract
Objective The objective of this study was to evaluate efficacy and safety of low-dose risperidone for treating psychosis of Alzheimer disease (AD). Method The authors conducted a randomized, eight-week, double-blind, placebo-controlled, multicenter trial involving nursing home residents diagnosed with AD and psychosis. Four hundred seventy-three patients were randomly assigned to placebo (N = 238) or 1.0 to 1.5 mg risperidone per day (N = 235). Coprimary efficacy end points were: changes in scores on the Behavioral pathology in Alzheimer's Disease (BEHAVE-AD) Psychosis subscale and Clinical Global Impression of Change (CGI-C). Protocol-specified subgroup analyses were performed by demographics and dementia severity. Results Efficacy analysis included 416 patients. Both groups improved significantly on the BEHAVE-AD Psychosis subscale and CGI-C with no significant difference between groups. In the subgroups analyses, a statistically significant treatment by Mini-Mental Status Examination (MMSE) interaction on the CGI-C (F([2,381]) = 3.90, p = 0.021) was observed with patients with more severe dementia (MMSE Conclusion This trial did not confirm earlier findings in this population.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several trials have investigated risperidone use in AD in the context of alleviating behavioral and psychological symptoms rather than as a potential treatment for AD.
“While several trials have investigated risperidone use in AD, this has been in the context of alleviating behavioral and psychological symptoms (e.g., agitation, hallucinations, and delusions) observed in some individuals with AD, rather than as a potential treatment for AD (Brodaty et al., 2003;Mintzer et al., 2006).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Mintzer et al., 2006
Cites
Incidence of and risk factors for hallucinations and delusions in patients with probable AD
Paulsen, J. S., Salmon, D. P., Thal, L. J., Romero, R., Weisstein–Jenkins, C., Galasko, D., Hofstetter, C. R., Thomas, R., Grant, I., & Jeste, D. V. (2000) · Neurology · doi:10.1212/wnl.54.10.1965 · Cited by 254 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558 · see citing works
Management of Neuropsychiatric Symptoms in People with Dementia
Ballard, C., & Corbett, A. (2010) · CNS Drugs · doi:10.2165/11319240-000000000-00000 · Cited by 147 · see citing works
Trial of pimavanserin in dementia-related psychosis
Tariot, P. N., Cummings, J. L., Soto-Martin, M. E., Ballard, C., Erten-Lyons, D., Sultzer, D. L., Devanand, D. P., Weintraub, D., McEvoy, B., Youakim, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034634 · Cited by 145 · see citing works
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia
Mühlbauer, V., Möhler, R., Dichter, M. N., Zuidema, S. U., Köpke, S., & Luijendijk, H. J. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013304.pub2 · Cited by 117 · see citing works
Grossberg, G. T., Pejović, V., Miller, M. L., & Graham, S. M. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000200013 · Cited by 59 · see citing works
Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review
Grabowska, M. E., Huang, A., Wen, Z., Li, B., & Wei, W.-Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1257700 · Cited by 55 · see citing works
“, agitation, hallucinations, and delusions) observed in some individuals with AD, rather than as a potential treatment for AD (Brodaty et al., 2003; Mintzer et al., 2006).”
BackgroundProfyri, E., Leung, P., Huntley, J., & Orgeta, V. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101758 · Cited by 30 · see citing works
- Authors
- Mintzer, J., Greenspan, A., Caers, I., Van Hove, I., Kushner, S., Weiner, M., Gharabawi, G., & Schneider, L. S.
- Affiliations
- Medical University of South Carolina (US)
- Corresponding author
- Mintzer, Jacobo
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 14
- Issue
- 3
- Pages
- 280-291
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W1990224774
- Cited by
- 94
- References
- 1
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 7 · 2020: 2 · 2019: 5 · 2018: 4 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 7
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- risperidone, Alzheimer's disease, antipsychotic efficacy, treatment safety, nursing home residents, dementia severity, sleepiness, Clinical Global Impression of Change, Mini-Mental State Examination
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Long-Term Care, Male, Middle Aged, Nursing Homes, Prospective Studies, Psychotic Disorders, Antipsychotic Agents, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
